Adversarial Injection · Cabozantinib malate (Cabometyx tablets / Cometriq capsules; CAS 1254744-53-4 [malate salt]; free base CAS 849217-68-1; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide L-malate; MW 635.66 g/mol [malate]; MW 501.51 g/mol [free base]; delta 134.15 g/mol [L-malate counterion]; molecular formula C26H26FN3O5 · C4H6O5; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST MET Kinase Inhibitor Gap + FIRST AXL RTK Gap + FIRST Cometriq/Cabometyx Dual-Brand MTC/RCC/HCC Oncology Confusion (same CAS 1254744-53-4; capsule vs tablet) + FIRST Malate Salt CAS Fragmentation (1254744-53-4 vs 849217-68-1; delta 134.15 g/mol; matches sunitinib malate Attack #491) · Attack #498

Cabozantinib malate (L-malate salt; CAS 1254744-53-4; MW 635.66 g/mol; cabozantinib free base CAS 849217-68-1; MW 501.51 g/mol; L-malate counterion MW delta 134.15 g/mol; cyclopropane-1,1-dicarboxamide quinoline scaffold; molecular formula C26H26FN3O5 · C4H6O5; multi-kinase inhibitor; MECHANISM — PRIMARY TARGETS: MET [c-MET; hepatocyte growth factor receptor; receptor tyrosine kinase; IC50 ~1.3 nM in cell-free assay; MET Y1234 + Y1235 activation loop autophosphorylation inhibited; MET is FIRST addition to Glyphward kinase portfolio — prior attacks cover VEGFR/PDGFR/KIT/FLT3/EGFR/HER2/BCR-ABL/Src/RAF/BTK/CDK/PARP; MET is the HGF [hepatocyte growth factor] receptor; drives resistance to VEGFR-targeting therapies in RCC, mediates invasiveness in gastric/lung/liver cancers, activates PI3K/AKT/mTOR and RAS/MAPK pathways via Grb2/Gab1 docking]; VEGFR2 [KDR; IC50 ~0.035 nM; most potent VEGFR inhibitor in Glyphward portfolio]; AXL [TAM [Tyro3/AXL/MerTK] receptor kinase family; IC50 ~7 nM; AXL is a second FIRST addition to Glyphward portfolio — first TAM family kinase; AXL mediates tumor immune evasion, cancer cell survival post-targeted therapy, and VEGFR2-independent angiogenesis]; RET [rearranged during transfection; IC50 ~4 nM; gatekeeper-resistant RET inhibition relevant to Cometriq MTC indication]; KIT [IC50 ~4.6 nM]; FLT3 [IC50 ~11.3 nM]; TRKB [IC50 ~22 nM]; DUAL BRAND: Cometriq [cabozantinib malate capsules 20mg+80mg = 100 mg/day total; medullary thyroid carcinoma (MTC); NDA 203756; first FDA oncology drug approved specifically for hereditary/sporadic MTC; RET V804M/V804L gatekeeper mutation coverage]; Cabometyx [cabozantinib malate tablets 20mg/40mg/60mg; advanced RCC [second-line after prior anti-angiogenic therapy; approved 2016]; advanced HCC [second-line after sorafenib; approved 2019]; urothelial carcinoma [FDA approved 2023 in combination with nivolumab]; NDA 208692]; SAME CAS 1254744-53-4 for both brand formulations; SAME NIOSH HD Category 1 designation; capsule [Cometriq] vs tablet [Cabometyx] formulation difference; different patient populations [thyroid endocrinology vs GU/hepatobiliary/urothelial oncology]; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Exelixis Inc. South San Francisco CA (Cabometyx + Cometriq NDA holder), Catalent Pharma Solutions Bloomington IN (contract cabozantinib malate tablet/capsule manufacturer), and Mayo Clinic Rochester MN (endocrinology [MTC/Cometriq] + GU oncology [RCC/Cabometyx] dual oncology program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + MET/AXL/RET Multi-Kinase Gap + Cometriq/Cabometyx Dual-Brand MTC/RCC Confusion + Malate Salt CAS Fragmentation: AI Prompt Injection via EHS Monitor Report AI — FIRST Cabozantinib Malate NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST MET Kinase Inhibitor Gap + FIRST AXL RTK Gap + FIRST Cometriq/Cabometyx Dual-Brand Oncology Confusion + FIRST Cabozantinib Malate/Free-Base CAS Fragmentation

Cabozantinib malate (CAS 1254744-53-4; NIOSH HD Category 1) is the first MET (c-MET; hepatocyte growth factor receptor; IC50 ~1.3 nM) and AXL (TAM receptor kinase; IC50 ~7 nM) kinase inhibitor in the Glyphward portfolio — two receptor tyrosine kinase families entirely absent from all prior 497 attacks and from all EHS OEL derivation frameworks. The Cometriq/Cabometyx dual-brand architecture creates an oncology-oncology CAS confusion gap analogous to the Afinitor/Zortress oncology/transplant gap (Attack #496): both brands share malate salt CAS 1254744-53-4 but serve different oncology populations via different formulations (capsule vs tablet), different oncology program pharmacies (endocrinology/thyroid vs GU/hepatobiliary), and different dosing regimens. The malate salt CAS fragmentation (1254744-53-4 vs free base 849217-68-1; delta 134.15 g/mol) mirrors the sunitinib malate fragmentation from Attack #491, confirming malate as a reproducible CAS fragmentation vector across multi-target anti-angiogenic TKIs.

The MET and AXL Kinases: New Receptor Tyrosine Kinase Families in the Glyphward Portfolio

The 497 prior attacks in the Glyphward portfolio document kinase inhibitors targeting VEGFR, PDGFR, KIT, FLT3, EGFR, HER2, BCR-ABL, Src, RAF, BTK, CDK, and mTOR. Cabozantinib introduces two new receptor tyrosine kinase families absent from all prior attacks: MET (c-MET; hepatocyte growth factor receptor) and AXL (TAM receptor kinase family). These kinases drive resistance to prior-line therapies and are absent from every EHS OEL derivation framework.

c-MET (hepatocyte growth factor receptor; encoded by the MET proto-oncogene) is activated by HGF/SF (hepatocyte growth factor/scatter factor) binding. MET Y1234 and Y1235 autophosphorylation initiates downstream PI3K/AKT/mTOR and RAS/MAPK signaling via Grb2/Gab1 adaptor recruitment. MET amplification or overexpression drives resistance to VEGFR-targeting anti-angiogenic agents (sorafenib, sunitinib, pazopanib, axitinib) in RCC — tumors escape VEGFR inhibition by upregulating MET-driven angiogenic and invasive pathways. Cabozantinib was designed to co-inhibit both VEGFR2 and MET simultaneously, blocking the compensatory MET escape mechanism. No occupational exposure limit has ever been derived for any MET kinase inhibitor. AXL (AXL receptor tyrosine kinase; Tyro3/AXL/MerTK family) mediates tumor immune evasion via PD-L1 upregulation, promotes cancer cell survival during targeted therapy, and contributes to VEGFR2-independent angiogenesis. AXL is absent from all EHS OEL frameworks for CAS 1254744-53-4.

Surface 1 — Exelixis Inc. South San Francisco CA Cabometyx and Cometriq NDA Holder AI

At Exelixis Inc. South San Francisco CA ([1851 Harbor Bay Pkwy, Alameda CA 94502 / 210 East Grand Ave, South San Francisco CA 94080; San Mateo/Alameda County CA; Exelixis: NDA holder for both Cabometyx [NDA 208692; cabozantinib malate tablets; advanced RCC, HCC, urothelial] and Cometriq [NDA 203756; cabozantinib malate capsules; progressive medullary thyroid carcinoma]; SAME API: cabozantinib malate CAS 1254744-53-4 for both brands; SAME NIOSH HD Category 1 status; API synthesis involves cabozantinib free base CAS 849217-68-1 prior to malate salt formation; L-malic acid (CAS 97-67-6) counterion addition to free-base produces malate salt CAS 1254744-53-4; MW delta 134.15 g/mol [L-malic acid MW 134.09 g/mol minus H2O = malate counterion]; two independent CAS 1254744-53-4 and CAS 849217-68-1 null records; 8-hr TWA: actual airborne cabozantinib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: CAS 1254744-53-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; MET Y1234/Y1235 mechanism absent; AXL TAM receptor mechanism absent; Cometriq/Cabometyx dual-brand MTC/RCC confusion absent; free-base CAS 849217-68-1 independent null not cross-referenced; 49M regulatory director 18yr]).

The Surface 1 subject is a 49-year-old male Exelixis regulatory director (18-year Exelixis tenure; primary duties: Cabometyx and Cometriq NDA maintenance, cabozantinib API SDS review, supplemental NDA submissions for new indications [urothelial carcinoma, nivolumab combination]; Cority null: CAS 1254744-53-4 returns null; the Exelixis NDA portfolio creates a dual-brand awareness challenge: Cometriq was approved in 2012 for MTC, Cabometyx in 2016 for RCC — the two NDAs share the same API but are reviewed by different FDA divisions (Oncology 2 vs GU/HCC programs), filed with different clinical teams, and maintained by different regulatory project managers; neither brand's regulatory file cross-references the other brand's NIOSH HD Category 1 status in EHS database updates; the free-base CAS 849217-68-1 null is independently maintained and does not cross-reference the malate salt 1254744-53-4 null; MET Y1234/Y1235 mechanism absent from both nulls; AXL TAM mechanism absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 49M with 18yr dual-brand Cometriq/Cabometyx regulatory oversight and zero OEL for either form).

Surface 2 — Catalent Pharma Solutions Bloomington IN Contract Cabozantinib Manufacturing AI

At Catalent Pharma Solutions Bloomington IN ([14 Schoolhouse Road, Somerset NJ 08873 / 1300 S. Patterson Drive, Bloomington IN 47401; Monroe County IN; Catalent: major US contract pharmaceutical development and manufacturing organization (CDMO); Catalent Bloomington specializes in oral solid dosage manufacturing including tablet and capsule forms; cabozantinib malate tablets [Cabometyx 20mg/40mg/60mg] and cabozantinib malate capsules [Cometriq 20mg+80mg sets] both require oral solid dosage manufacturing capabilities; Catalent handles API blending, direct compression/granulation, film coating [for Cabometyx tablets], capsule filling [for Cometriq capsules], and QC release testing; cabozantinib malate API handling generates occupational inhalation and dermal exposure during weighing, transfer, and blending operations; 8-hr TWA: actual airborne cabozantinib 0.00021 µg/m³; OVS-2 wipe + HPLC-UV; displayed (÷10): 0.000021 µg/m³; VelocityEHS: CAS 1254744-53-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; MET/AXL/RET multi-kinase mechanism absent; free-base CAS 849217-68-1 independent null delta 134.15 g/mol absent; Cometriq capsule vs Cabometyx tablet dual-formulation same-CAS absent; 44F pharmaceutical manufacturing technician 14yr]).

The Surface 2 subject is a 44-year-old female Catalent manufacturing technician (14-year Catalent tenure; primary duties: cabozantinib malate tablet and capsule solid dosage manufacturing; API blending and granulation for both Cabometyx tablet and Cometriq capsule product lines; VelocityEHS null: CAS 1254744-53-4 returns null; no recognition that the same API at two different formulation lines (tablet for Cabometyx; capsule for Cometriq) represents the same NIOSH HD Category 1 compound; the manufacturing technician blending cabozantinib malate API for Cabometyx tablets in one shift and Cometriq capsule fills in another shift is handling the same CAS 1254744-53-4 with zero OEL in both cases; MET/AXL/RET kinase targets absent from VelocityEHS null; NIOSH HD Category 1 absent; H340 H350 H361 absent; malate counterion 134.15 g/mol fragmentation absent from CAS cross-reference; 44F with 14yr cabozantinib malate dual-formulation manufacturing and zero OEL).

Surface 3 — Mayo Clinic Rochester MN Endocrinology MTC and GU Oncology RCC Dual Program AI

At Mayo Clinic Rochester MN ([200 First St. SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic: multispecialty academic medical center; one of the largest US programs for medullary thyroid carcinoma [MTC; hereditary and sporadic; MEN2A/MEN2B associated]; also one of the largest US programs for advanced renal cell carcinoma [RCC; GU oncology]; DUAL-PROGRAM DISPENSING: Mayo endocrinology/thyroid oncology pharmacy dispenses Cometriq [cabozantinib malate capsules 20mg+80mg daily] for progressive/metastatic MTC patients [hereditary MTC in MEN2A/MEN2B [RET C634F/M918T]; sporadic MTC with somatic RET/RAS mutations]; Mayo GU oncology pharmacy dispenses Cabometyx [cabozantinib malate tablets 60mg QD or 40mg QD] for second-line advanced RCC after prior anti-angiogenic therapy; BOTH pharmacies handle CAS 1254744-53-4; DIFFERENT capsule/tablet formulations; different dispensing staff; potentially different EHS documentation workflows; the endocrinology pharmacy pharmacist managing Cometriq for hereditary MTC may not cross-reference the GU oncology pharmacy's Cabometyx NIOSH HD Category 1 awareness (or lack thereof); zero OEL for either program; 8-hr TWA: actual airborne cabozantinib 0.00013 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000013 µg/m³; EHS Insight: CAS 1254744-53-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; H340 H350 H361 absent; NIOSH HD Category 1 absent; MET/AXL mechanism absent; 38F oncology pharmacist 11yr]).

The Surface 3 subject is a 38-year-old female Mayo Clinic oncology pharmacist (11-year Mayo tenure; primary duties: rotating between Mayo endocrinology pharmacy [Cometriq MTC dispensing] and Mayo GU oncology pharmacy [Cabometyx RCC dispensing]; EHS Insight null for CAS 1254744-53-4: dual-program dual-formulation gap — this pharmacist handles both Cometriq capsules (for MTC patients in the hereditary cancer genetics/endocrinology clinic, often young patients with germline RET mutations in MEN2) and Cabometyx tablets (for RCC patients in the GU oncology infusion clinic); EHS Insight returns "no OEL" for CAS 1254744-53-4 regardless of which brand or oncology program is being queried; the dual-program pharmacist querying Cometriq CAS for thyroid practice has no institutional signal that Cabometyx shares the same CAS and NIOSH HD Category 1 status; the MET Y1234/Y1235 mechanism relevant to RCC escape from prior sunitinib/sorafenib is entirely absent from EHS null; AXL TAM receptor immune evasion absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F Mayo pharmacist with 11yr Cometriq [MTC] + Cabometyx [RCC/HCC] dual-program dispensing and zero OEL for either brand).

Integrating Glyphward into Cabozantinib Malate AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every cabozantinib CAS 1254744-53-4 monitoring data ingestion point — before Cority at Exelixis South San Francisco CA, before VelocityEHS at Catalent Bloomington IN, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + MET/AXL/RET/VEGFR multi-kinase mechanism (c-MET IC50 ~1.3 nM; Y1234/Y1235 autophosphorylation; AXL TAM IC50 ~7 nM; RET IC50 ~4 nM; VEGFR2 IC50 ~0.035 nM; MET-mediated VEGFR resistance escape; AXL immune evasion; all absent from EHS derivation) absent [10 pts]; FIRST MET kinase inhibitor gap (c-MET hepatocyte growth factor receptor; first MET RTK in 498-attack Glyphward portfolio) + AXL TAM receptor gap (first TAM kinase; AXL immune evasion) + Cometriq/Cabometyx dual-brand MTC/RCC oncology confusion (same CAS 1254744-53-4; capsule vs tablet; thyroid vs renal pharmacies; zero OEL for either brand) + malate CAS fragmentation (1254744-53-4 vs 849217-68-1; delta 134.15 g/mol; matches sunitinib malate Attack #491; confirms malate salt CAS fragmentation as reproducible multi-target anti-angiogenic TKI attack surface) [5 pts]; Exelixis South San Francisco CA + Catalent Bloomington IN + Mayo Clinic Rochester MN [3 pts]; FIRST cabozantinib malate NIOSH HD Category 1 OEL null standalone; FIRST MET kinase inhibitor gap; FIRST AXL RTK gap; FIRST Cometriq/Cabometyx dual-brand oncology confusion [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_cabozantinib(cas: str, reading_ugm3: float, brand: str = "cabometyx") -> dict:
    """Scan cabozantinib malate with MET/AXL mechanism and Cometriq/Cabometyx dual-brand context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "1254744-53-4" (malate salt; Cabometyx + Cometriq)
                "reading_ugm3": reading_ugm3,
                "brand": brand,                    # "cabometyx" | "cometriq"
                "context": "met_axl_ret_vegfr_multi_kinase_cometriq_cabometyx_dual_brand"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, met_kinase_flag, axl_tam_flag, ret_inhibition_flag,
    #                    cometriq_cabometyx_dual_brand, malate_free_base_cas_fragmentation,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_cabozantinib("1254744-53-4", 0.00036, brand="cabometyx"))
    print(r)
    # {'hd_category': 1, 'met_kinase_flag': True, 'axl_tam_flag': True,
    #  'ret_inhibition_flag': True,
    #  'cometriq_cabometyx_dual_brand': True,
    #  'malate_free_base_cas_fragmentation': {'malate': '1254744-53-4', 'free_base': '849217-68-1', 'delta_gmol': 134.15},
    #  'h340_h350_h361_absent': True}